Aripiprazole as protector against COVID-19 mortality Munecas et al 2024

leokitten

leokitten

Senior Member (Voting Rights)
https://www.nature.com/articles/s41598-024-60297-y
The relation of antipsychotics with severe Coronavirus Disease 19 (COVID-19) outcomes is a matter of debate since the beginning of the pandemic. To date, controversial results have been published on this issue. We aimed to prove whether antipsychotics might exert adverse or protective effects against fatal outcomes derived from COVID-19. A population-based retrospective cohort study (January 2020 to November 2020) comprising inpatients (15,968 patients) who were at least 18 years old and had a laboratory-confirmed COVID-19 infection. Two sub-cohorts were delineated, comprising a total of 2536 inpatients: individuals who either had no prescription medication or were prescribed an antipsychotic within the 15 days preceding hospitalization. We conducted survival and odds ratio analyses to assess the association between antipsychotic use and mortality, reporting both unadjusted and covariate-adjusted results. We computed the average treatment effects, using the untreated group as the reference, and the average treatment effect on the treated, focusing solely on the antipsychotic-treated population. Among the eight antipsychotics found to be in use, only aripiprazole showed a significant decrease in the risk of death from COVID-19 [adjusted odds ratio (OR) = 0.86; 95% CI, 0.79–0.93, multiple-testing adjusted p-value < 0.05]. Importantly, these findings were consistent for both covariate-adjusted and unadjusted analyses. Aripiprazole has been shown to have a differentiated beneficial effect in protecting against fatal clinical outcome in COVID-19 infected individuals. We speculate that the differential effect of aripiprazole on controlling immunological pathways and inducible inflammatory enzymes, that are critical in COVID19 illness, may be associated with our findings herein.
Click to expand...
 
Fascinating.

Note that the doses used commonly for apiprazole (5-30mg) and therefore likely what this study is referring to are quite different than the dose some ME patients report improvement from which is more like 0.1mg-4mg.
 
Yann04 said:
Fascinating.

Note that the doses used commonly for apiprazole (5-30mg) and therefore likely what this study is referring to are quite different than the dose some ME patients report improvement from which is more like 0.1mg-4mg.
Click to expand...

Well yes because but this study is talking about COVID mortality, not improvement in ME symptoms. We’ve also discussed at length here and elsewhere the reasons why even much lower dosages aripiprazole are still quite potent (eg dopamine system interactions at low dosages and high occupancy) The take home message is that aripiprazole, as previous research has also suggested, has some surprising and quite potent immunomodulatory effects, and while it’s been marketed and used as an antipsychotic and antidepressant adjunct it’s quite interesting how it can affect the immune system and immunometabolism.
 
This is SO DANGEROUS! This is an off label use, and it results in some very serious side effects which can and has led to stroke and death. I've been on it for 3 years and have just been in a virtual ward at home because of it. ME Association Statement: Aripiprazole (Abilify) & ME/CFS - The ME Association

I'm withdrawing consent under Montgomery v. Lanarkshire Healthboard [2015] and refusing to take it anymore. I've been on 20mg daily down to 10 mg, now down to 5mg. I've had severe ME/CFS since 2011 and absolutely no beneficial difference to ME symptoms, except serious side effects relating to drug, and which are now permanent, such as dangerously high blood pressure which I didn't have before being prescribed in the UK as an anti-psychotic drug because I was sectioned. I haven't read this research, nor do I intend to.
 
Maat said:
This is SO DANGEROUS! This is an off label use, and it results in some very serious side effects which can and has led to stroke and death. I've been on it for 3 years and have just been in a virtual ward at home because of it. ME Association Statement: Aripiprazole (Abilify) & ME/CFS - The ME Association
Click to expand...

I’m sorry that you feel that you’ve been harmed by high dose Abilify.

However many thousands of ME/CFS patients have benefited, some very substantially, from low dose Abilify.
 
Jaybee00 said:
I’m sorry that you feel that you’ve been harmed by high dose Abilify.

However many thousands of ME/CFS patients have benefited, some very substantially, from low dose Abilify.
Click to expand...
For those it has helped I am genuinely pleased. However, it must first be safe.

There's a difference between feeling that I've been harmed, and having a note of that harm in the form of new diagnoses which are the common side effects of this drug on my medical records and for which I have been treated such as dangerously high blood pressure and for which I have just in the last few weeks been placed on a virtual hospital ward. That's just one of the side effects of long term use. I've been on it since October 2020, before the Stanford study, which the ME Association reference, took place.
 
Yann04 said:
Wouldn’t anti-inflammatoiry properties would be expected to be linked to worse COVID outcomes because inflammation is part of how the immune system fights COVID? I guess anti-inflammatory properties would help with cytokine storms which may be linked to worse COVID outcomes.
Click to expand...

People get very sick and die from COVID because their immune systems go haywire in response to the virus. Inflammation is only good in the beginning but continued hyperinflammation and immune dysregulation causes damage and possibly death
 
You must log in or register to reply here.
Back
Top Bottom